OTR Therapeutics and LG Chem have entered into a strategic framework agreement to identify, evaluate and develop novel oncology assets originating from China’s biopharmaceutical sector.

• Division of Responsibilities: OTR Therapeutics will lead asset sourcing, technical evaluation, preclinical research and early clinical development in China, while LG Chem will be responsible for global clinical development, regulatory strategy and commercialisation outside China.
• Commercial Framework: Individual development programmes will be governed by separate agreements, with OTR Therapeutics eligible for upfront payments and development, regulatory and commercial milestone payments.
• Co-Development Option: OTR Therapeutics may participate in global development and obtain certain global rights for selected programmes that advance into late-stage clinical development.

This summary is based on a news article published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.